Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Ltd. has entered into an agreement with Visara, Inc. to develop and commercialize VIS-101, a novel bifunctional biologic, in Greater China and other Asian markets. This strategic collaboration allows Everest Medicines to expand into the ophthalmology sector, adding a commercially attractive asset to its late-stage product pipeline, potentially enhancing its market positioning and addressing significant unmet medical needs in the region.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative medicines. The company is expanding its product pipeline with a focus on late-stage products, and it is now entering the ophthalmology sector, which has significant unmet medical needs.
Average Trading Volume: 5,108,332
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.27B
See more insights into 1952 stock on TipRanks’ Stock Analysis page.